Gina DeNicola, Ph.D.
H. Lee Moffitt Cancer Center & Research Institute
Funded by the American Lung Association of the Upper Midwest
Changes in Cell Signaling Pathway Could Shed Light on Lung Cancer
Changes in the pathways in which cells signal one another are implicated in the development of cancer. One of the most common pathways mutated in lung cancer is called NRF2/KEAP1. In order to understand the role of the NRF2/KEAP1 pathway in cancer development and the emergence of drug resistance, we have generated NRF2 mutant mice to study its function in lung cancer. We will use this model to study the role of NRF2 mutation in both tumor initiation and progression. We will also investigate whether therapy that inhibits NRF2 itself or exploits NRF2 activation would eradicate NRF2 mutant tumors. This could lead to new therapies for the treatment of lung cancer patients with alterations in the NRF2/KEAP1 pathway.